Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia

27 Nov 2018

Abstract excerpt

// Nikhil Patkar 1, * , Rohan Kodgule 1, 5, * , Chinmayee Kakirde 1 , Goutham Raval 1 , Prasanna Bhanshe 1 , Swapnali Joshi 1 , Shruti Chaudhary 1 , Y. Badrinath 1 , Sitaram Ghoghale 1 , Shraddha Kadechkar 1 , Syed Hasan Khizer 2 , Sadhana Kannan 3 , Dhanalaxmi Shetty 4 , Anant Gokarn 2 , Sachin Punatkar 2 , Hasmukh Jain 2 , Bhausaheb Bagal 2 , Hari Menon 6 , Manju Sengar 2 , Navin Khattry 2 , Prashant Tembhare 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Single-cell and spatial transcriptomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30564301
DOI: 10.18632/oncotarget.26400

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemiaPMID 30564301Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.Semantic proximity Read ↗

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and PerspectivesSemantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Semantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.Semantic proximity Read ↗

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.Semantic proximity Read ↗

Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1Semantic proximity Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.